Onconetix, Inc. (ONCO) is a Biotechnology company in the Healthcare sector, currently trading at $0.76. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 0 out of 7 criteria passed.
Valuation: ONCO trades at a trailing Price-to-Earnings (P/E) of -0.6 (S&P 500 average ~25).
Financials: revenue is $815,371, +2074.8%/yr average growth. Net income is $14M (loss), growing at -53.2%/yr. Net profit margin is -1721% (negative). Gross margin is 77.6% (+2005.5 pp trend).
Balance sheet: total debt is $48,774 against $16M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.66 (tight liquidity). Debt-to-assets is 0.2%. Total assets: $25M.
Analyst outlook: 1 / 2 analysts rate ONCO as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 40/100 (Partial), Income 10/100 (Fail).
